The DOI matches its Crossref record.
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin
Open accessAbstract
Cisplatin is an anticancer drug that has enjoyed remarkable success against testicular tumors, but dose limiting side-effects have limited its application against a broader range of cancers. Previous studies have shown that high-mobility group (HMG) domain proteins such as HMG1 sensitize cells to cisplatin by shielding its major DNA adducts from nucleotide excision repair. Estrogen treatment increases HMG1 mRNA levels in breast cancer MCF-7 cells. Herein, we describe that treatment of human cancer cells having steroid hormone receptors with the appropriate hormone, estrogen and/or progesterone, significantly increases the potency of cisplatin and its analogue carboplatin by causing the overexpression of HMG1. These findings suggest that the proper combination of these drugs, which are already approved by the Food and Drug Administration, could have potential benefit in treating tumors such as ovarian or breast that carry the hormone receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Self-citationCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Self-citationCisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Self-citationKang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
New metal complexes as potential therapeutics
Zhang, C. X., & Lippard, S. J. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00081-4 · Cited by 946
Self-citationFuertes, M. A., Alonso, C., & Pérez, J. M. (2003) · Chemical Reviews · doi:10.1021/cr020010d · Cited by 893
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
HMG1 and 2, and related ‘architectural’ DNA-binding proteins
Thomas, J. O., & Travers, A. A. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01801-1 · Cited by 618
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Redox activation of metal-based prodrugs as a strategy for drug delivery
Graf, N., & Lippard, S. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.007 · Cited by 523
Self-citationHigh-mobility group box 1 and cancer
Tang, D., Kang, R., Zeh III, H. J., & Lotze, M. T. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.014 · Cited by 512
Platinum Complexes as Anticancer Agents
Kostova, I. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206775246458 · Cited by 493
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
HMGB proteins and gene expression
Agresti, A., & Bianchi, M. E. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00023-6 · Cited by 394
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Mini‐review: The nuclear protein HMGB1 as a proinflammatory mediator
Erlandsson Harris, H., & Andersson, U. (2004) · European Journal of Immunology · doi:10.1002/eji.200424916 · Cited by 371
Müller, S., Ronfani, L., & Bianchi, M. E. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2003.01296.x · Cited by 367
Platinum Drug Distribution in Cancer Cells and Tumors
Klein, A. V., & Hambley, T. W. (2009) · Chemical Reviews · doi:10.1021/cr9001066 · Cited by 351
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug
Graf, N., Bielenberg, D. R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O. C., & Lippard, S. J. (2012) · ACS Nano · doi:10.1021/nn301148e · Cited by 327
Self-citationSmith, S. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01780-1 · Cited by 314
DNA?protein crosslinks: their induction, repair, and biological consequences
BARKER, S., WEINFELD, M., & MURRAY, D. (2005) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2004.11.003 · Cited by 312
Advances in Platinum Chemotherapeutics
Harper, B. W., Krause‐Heuer, A. M., Grant, M. P., Manohar, M., Garbutcheon‐Singh, K. B., & Aldrich‐Wright, J. R. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201000148 · Cited by 267
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
Self-citationNuclear functions of the HMG proteins
Reeves, R. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.09.001 · Cited by 254
miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2
An, Y., Zhang, Z., Shang, Y., Jiang, X., Dong, J., Yu, P., Nie, Y., & Zhao, Q. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.123 · Cited by 218
“Overexpression of HMGB1 has been observed in several human cancers, such as breast cancer and colon cancer.(34,35) Importantly, HMGB1 contributes to chemoresistance in many types of cancer by activating Figure 5 miR-23b-3p inhibits autophagy in chemoresistant cells by negatively regulating ATG12 and HMGB2.”
Background
Metadata
- Authors
- He, Q., Liang, C. H., & Lippard, S. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 5768-5772
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2088445980
- Cited by
- 209
- References
- 0
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.